

Personalized Medicine

Part II: Development, Ethics, Regulation, Markets & Companies

By

Prof. K. K. Jain
MD, FRACS, FFPM
Jain PharmaBiotech
Basel, Switzerland

November 2021

A Jain PharmaBiotech Report

A U T H O R ' S B I O G R A P H Y

Professor K. K. Jain is a neurologist/neurosurgeon with specialist qualifications including Fellowships of the Royal Colleges of Surgeons in Australia and Canada. He has trained, practised and held academic positions in several countries including Switzerland, India, Iran, Germany Canada, and USA. After retirement from neurosurgery, Prof. Jain remains a consultant in neurology. He is also working in the biotechnology/biopharmaceuticals industry and is a Fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians of UK. Currently, he is the CEO of Jain PharmaBiotech.

Prof. Jain's 492 publications include 35 books (6 as editor + 29 as author) and 50 special reports, which have covered important areas in biotechnology, gene therapy and biopharmaceuticals. Books relevant to biotechnology and pharmaceuticals include "Role of Nanobiotechnology in Molecular Diagnostics" (2006), "Handbook of Nanomedicine" (Humana/Springer 2008; Chinese edition, Peking University Press 2011, 2nd ed Springer 2012, 3rd ed 2017), "Textbook of Personalized Medicine (Springer 2009; Japanese ed 2012; 2nd ed Springer 2015, 3rd ed 2021), "Handbook of Biomarkers" (Springer 2010; Chinese edition by Chemical Industry Press 2016, 2nd edition Springer 2017), "Handbook of Neuroprotection" (Springer 2011, 2nd ed 2019), "Drug-induced Neurological Disorders", 4th ed, Springer 2021), "Applications of Biotechnology in Cardiovascular Therapeutics" (Springer 2011), "Applications of Biotechnology in Neurology" (Springer 2013), and "Applications of Biotechnology in Oncology" (Springer 2014). He has edited "Drug Delivery Systems", 2nd ed (Springer 2014, 3rd edn 2019) and "Applied Neurogenomics" (Springer 2015). Currently, he is writing "The Handbook of Alzheimer Disease" to be published by Springer in 2022.

Prof. Jain has been interested in using biotechnology to develop personalized medicine since 1997. He has also lectured and conducted several workshops on personalized medicine worldwide. Most recently, he was Visiting Professor of Personalized Medicine at Almaty Medical University in Kazakhstan in 2018. During a period of 2 weeks, he delivered 30 lectures to cover important areas of personalized medicine for physicians and students. A transcript of lectures in Russian was published as a book "Essentials of Personalized Medicine" (LITERRA Publishing House, Moscow, 2019).

A B O U T T H I S R E P O R T

Prof. Jain wrote the first report on Personalized Medicine in 1998, which was published by Decision Resources Inc. This was the first recorded use of the term "personalized medicine" in medical literature. The second edition was published in 2001 by Informa Publications, London. Since 2003, the report is published and continuously updated and rewritten at Jain PharmaBiotech.

November 2021 (first edition published in 1998 by Decision Resources Inc)
Copyright ©2021 by

Jain PharmaBiotech
Bläsiring 7
CH-4057 Basel
Switzerland

Tel & Fax: +4161-6924461
Email: info@pharmabiotech.ch
Web site: http://pharmabiotech.ch/

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, or otherwise without the prior written permission of the Publisher. This report may not be lent, resold or otherwise traded in any manner without the consent of the Publisher. While all reasonable steps have been taken to ensure the accuracy of the information presented, the Publisher cannot accept responsibility for inadvertent errors or omissions.

T A B L E O F C O N T E N T S

11. Development of Personalized Medicine	9
Introduction	9
Non-genomic factors in the development of personalized medicine	9
Personalized medicine based on circadian rhythms.....	9
Cytomics as a basis for personalized medicine	11
Intestinal microflora	11
<i>Gut microbiome compared to human genome.....</i>	11
<i>Metabolic interactions of the host and the intestinal microflora</i>	12
Role of drug delivery in personalized medicine.....	12
Personalized approach to clinical trials	12
<i>Adaptive clinical trials.....</i>	13
<i>Bayesian approach in biomarker-based clinical trials</i>	14
<i>Clinical trials of therapeutics and companion diagnostics.....</i>	15
<i>Clinical trials on selected subpopulations of patients.....</i>	15
<i>Clinical trials networks.....</i>	15
<i>Creative clinical trial design.....</i>	16
<i>Individualizing risks and benefits in clinical trials</i>	16
Players in the development of personalized medicine.....	17
Personalized Medicine Coalition.....	17
Role of pharmaceutical industry	18
<i>Repositioning of drugs for personalized medicine</i>	19
<i>Discovery of personalized medicines.....</i>	19
<i>Personalized drug delivery</i>	20
<i>Production and distribution of personalized medicines.....</i>	20
Role of biotechnology companies	21
Role of life sciences industries	21
Role of biomedical engineering in wearable devices for personalized healthcare	21
Role of molecular imaging in personalized medicine	22
<i>Molecular imaging for personalized drug development in oncology</i>	22
<i>Molecular imaging and CNS drug development</i>	24
<i>Companies involved in molecular imaging</i>	25
Role of the clinical laboratories	25
Role of the US government in personalized medicine	26
<i>Precision Medicine Initiative</i>	27
<i>Department of Health and Human Services and personalized medicine</i>	29
<i>Agency for Healthcare Research and Quality.....</i>	30
<i>Comparative effectiveness research</i>	30
Role of the US Government agencies in personalized medicine	32
<i>NIH's Roadmap Initiative for Medical Research</i>	32
<i>NIH and personalized medicine</i>	32
<i>NIH collaboration with the FDA</i>	33
<i>NIH and Genetic Testing Registry.....</i>	33
<i>National Human Genome Research Institute.....</i>	33
<i>National Institute of General Medical Sciences</i>	33
<i>National Institute of Standards and Technology</i>	36
<i>Role of the Centers for Disease Control.....</i>	36
Role of academic institutions and health centers in the US	36
<i>Baylor College of Medicine.....</i>	36
<i>California Initiative to Advance Precision Medicine</i>	37
<i>Children's Hospital of Los Angeles</i>	37
<i>Clinical Proteomics Program of NCI & FDA</i>	37
<i>Coriell Personalized Medicine Collaborative™</i>	38
<i>Delaware Valley Personalized Medicine Project.....</i>	38
<i>Duke University' Center for Genomic and Computational Biology.....</i>	39
<i>Evaluation of genetic tests and genomic applications</i>	39
<i>Indiana University Institute for Personalized Medicine.....</i>	40
<i>Inova Center for Personalized Health</i>	40
<i>Institute of Medicine's role in personalized medicine</i>	41
<i>Jackson Laboratory for Genomic Medicine</i>	41
<i>Johns Hopkins Center for Personalized Cancer Medicine Research</i>	41
<i>Mayo Clinic's Centers for Individualized Medicine</i>	42
<i>Mt. Sinai Medical Center's Personalized Medicine Research Program</i>	43
<i>North Shore University's Center for Personalized Medicine.....</i>	43
<i>P4 Medicine Institute</i>	43
<i>Personalized Medicine Partnership of Florida</i>	44
<i>Personalized oncology at Massachusetts General Hospital</i>	44
<i>Personalized oncology at Oregon Health & Science University</i>	44
<i>Pharmacogenetics Research Network and Knowledge Base.....</i>	45

<i>Southeast Nebraska Cancer Center's Personalized Medicine Network</i>	45
<i>Spectrum Health Center for personalized cancer care</i>	45
<i>Stanford Center for Genomics and Personalized Medicine</i>	46
<i>UAB-HudsonAlpha Center for Genomic Medicine</i>	46
<i>University of Colorado's Center for Personalized Medicine</i>	46
<i>UNC Institute for Pharmacogenomics and Individualized Therapy</i>	47
<i>Weill Cornell's Englander Institute for Precision Medicine</i>	47
<i>Wisconsin Genomics Initiative</i>	48
Role of academic collaborations with companies	48
<i>New York Genome Center</i>	48
Role of healthcare organizations	48
Role of the medical profession	49
<i>The American Medical Association and personalized medicine</i>	49
<i>Education of the physicians</i>	49
<i>Off-label prescribing and personalized medicine</i>	50
<i>Medical education</i>	50
Role of patients	50
<i>Consumer genomics</i>	51
<i>Monitoring of patient compliance with therapy</i>	52
<i>Public attitude towards personalized medicine</i>	52
<i>Patient participation in disease management decisions</i>	53
<i>Patient engagement in clinical trials of personalized medicine</i>	54
Role of genetic banking systems and databases	54
Role of biobanks in development of personalized medicine	54
UK Biobank	55
Biobanking and development of personalized medicine in EU	55
<i>BBMRI-ERIC</i>	55
CARTaGENE for biobanks in Canada	56
Personalized medicine based on PhysioGenomics™ technology	56
Role of bioinformatics in development of personalized medicine	57
Biosimulation techniques for developing personalized medicine	58
Biosensing and wearable devices for monitoring of health	58
<i>Devices for detection of digital biomarkers</i>	59
Clinical decision support systems	59
Digitalized medicine	59
Genomic data analysis	60
Integration of omics data by deep learning	60
Exploration of disease-gene relationship	60
Health information management	60
Electronic health records	61
<i>Analysis of -omic and EHR data of the patient</i>	61
<i>Cost of EHR and savings on healthcare expenses in the US</i>	62
<i>EHRs and genome-wide studies</i>	62
<i>Linking patient medical records and genetic information</i>	62
<i>Management of personal genomic data</i>	63
<i>Use of EHRs for improving safety of new medicines</i>	63
<i>Use of EHRs for genetic research</i>	63
<i>Use of EHRs for personalized drug discovery and development</i>	64
Personalized prognosis of disease	64
Integration of technologies for personalized medicine	65
Global scope of personalized medicine	65
Global Alliance for Genomics and Health	65
Precision medicine project of World Economic Forum	66
Personalized medicine in Canada	66
Personalized medicine at Ontario Institute for Cancer Research	67
Personalized Medicine Partnership for Cancer in Quebec	68
Quebec Center of Excellence in Personalized Medicine	69
Personalized medicine in the EU	69
European Personalized Medicine Diagnostics Association	69
European Ubiquitous Pharmacogenomics project	70
UK National Health Service and medical genetics	70
UK's 100,000 Genomes project	71
UK's Precision Medicine Catapult	71
Personalized medicine in France	71
Personalized medicine in Germany	71
Personalized medicine in Israel	72
Personalized medicine in Japan	73
Biobanks in Japan	73
Companion diagnostics in Japan	73
Cost-effectiveness of personalized medicine in Japan	73
Genetic testing in Japan	74

Initiative on rare and undiagnosed diseases	74
Personalized medicine in the developing countries.....	75
Personalized medicine in the Middle East	75
Personalized medicine in China	75
Personalized medicine in India	76
Personalized medicine in Africa	76
Advantages of personalized medicine.....	77
Limitations of personalized medicine.....	77
Non-genomic factors in response to drugs.....	78
Incidental findings in genetic screening and clinical sequencing	78
Future of personalized medicine.....	79
Personal Genome Project	80
<i>Genome-wide association studies.....</i>	<i>80</i>
<i>NHGRI's genomics vision for 2020.....</i>	<i>81</i>
<i>Genomics of aging in a genetically homogeneous population</i>	<i>81</i>
Translational science and personalized medicine	82
<i>Translation of genomic research into genetic testing for healthcare</i>	<i>82</i>
<i>Long-term behavioral effects of personal genetic testing.....</i>	<i>83</i>
Personalized predictive medicine.....	83
Connected health and personalized medicine.....	84
Opportunities and challenges for personalized medicine	84
<i>Comparative-effectiveness research and personalized medicine</i>	<i>84</i>
<i>Genetic testing and concerns about equality of healthcare.....</i>	<i>85</i>
<i>Impact of molecular diagnostics on personalized medicine</i>	<i>85</i>
<i>Initiative for delivery for precision medicine</i>	<i>85</i>
<i>IGNITE network – implementing personalized medicine in clinical care</i>	<i>86</i>
<i>Prospects and limitations of genetic testing</i>	<i>87</i>
<i>Personalized medicine and public health</i>	<i>88</i>
<i>Pharmacotyping.....</i>	<i>88</i>
<i>Medicine in the year 2025.....</i>	<i>88</i>
Concluding remarks about the future of personalized medicine	89
12. Ethical, Legal and Regulatory Aspects of Personalized Medicine	93
Introduction to ethical issues	93
Ethical issues of pharmacogenetics	93
Ethical aspects of genetic information.....	93
<i>Ethical issues of whole genome analysis</i>	<i>93</i>
<i>Privacy issues in personalized medicine</i>	<i>94</i>
<i>Genetic Information Nondiscrimination Act in the US</i>	<i>95</i>
<i>UNESCO and ethical aspects of personalized medicine</i>	<i>95</i>
Genotype-specific clinical trials	95
Ethical issues in use of digital technologies for personalized medicine	96
Social issues in personalized medicine	97
<i>Race and personalized medicine.....</i>	<i>97</i>
Legal issues of personalized medicine	99
Gene patents and personalized medicine.....	99
Regulatory aspects	100
FDA and personalized medicine.....	101
<i>FDA and molecular diagnostics in relation to personalized medicine.....</i>	<i>101</i>
<i>CLSI guideline for the use of RNA controls in gene expression assays</i>	<i>101</i>
<i>Evaluation of companion diagnostics/therapeutic</i>	<i>101</i>
<i>FDA oversight of laboratory developed tests.....</i>	<i>103</i>
<i>FDA guidelines for the role of IVD in personalized medicine</i>	<i>104</i>
<i>FDA oversight of NGS for diagnosis in personalized medicine</i>	<i>104</i>
<i>FDA's Clinical Databases Guidance</i>	<i>106</i>
<i>Analytical Validation Guidance</i>	<i>106</i>
<i>IVD device and drug co-development</i>	<i>106</i>
<i>FDA guidelines for personalized oncology</i>	<i>107</i>
<i>Regulatory aspects of pharmacogenetics.....</i>	<i>108</i>
<i>Regulation of direct-to-consumer genetic testing</i>	<i>108</i>
<i>Need for regulatory oversight of DTC.....</i>	<i>108</i>
<i>FDA and pharmacogenomics</i>	<i>111</i>
<i>FDA guidance for pharmacogenomic data submissions.....</i>	<i>112</i>
<i>Joint guidelines of the FDA and EU regulators for pharmacogenomics</i>	<i>112</i>
<i>Pharmacogenomic (PGx) information in drug labels.....</i>	<i>113</i>
<i>FDA guidelines for pharmacogenomics-based dosing</i>	<i>114</i>
<i>FDA and validation of biomarkers.....</i>	<i>114</i>
<i>FDA and predictive medicine</i>	<i>115</i>
13. Markets for Personalized Medicine	117
Introduction	117

Perceived financial concerns	117
Personalized medicine and orphan drug syndrome	117
Commercial aspects of pharmacogenomics.....	117
Cost of DNA testing.....	117
Cost of sequencing the human genome	118
Cost of genotyping	120
Cost of pharmacogenomics-based clinical trials.....	120
Business development of pharmacogenomic companies	121
Cost of personalized healthcare.....	121
The rising healthcare costs in the US	121
<i>Genetic testing and cost of healthcare</i>	122
Reducing healthcare costs by combining diagnostics with therapeutics	122
<i>Cost-effectiveness of pharmacogenetic testing</i>	123
<i>Cost-effectiveness of CYP genotyping-based pharmacotherapy</i>	123
<i>Cost effectiveness of HIV genotyping in treatment of AIDS</i>	124
<i>Cost-effectiveness of warfarin pharmacogenomics</i>	124
<i>Cost-benefit analysis of KRAS and BRAF screening in CRC</i>	124
<i>Lowering the high costs of cancer chemotherapy</i>	125
<i>Personalized dose reduction of pembrolizumab in cancer</i>	125
Overall impact of personalized medicine on healthcare	126
Drivers for the development of personalized medicine	126
Evolution of medicine as a driver for personalized therapy markets	126
Collaboration between the industry and the academia	127
Personalized medicine and drug markets	128
Segmentation of therapeutic drug markets.....	128
Reasons for increase of market values of personalized medicines.....	128
Growth of markets relevant to personalized medicine	129
<i>Biochips for diagnosis</i>	129
<i>Pharmacogenetics</i>	129
<i>Pharmacogenomics</i>	130
<i>Pharmacoproteomics</i>	130
<i>Point-of-Care</i>	130
<i>SNP market</i>	130
Markets for personalized medicines according to therapeutic areas	130
<i>Market for personalized cancer therapy</i>	131
<i>Markets for immuno-oncology</i>	131
Markets for personalized medicines according to geographical regions	131
Market opportunities for personalization of medicine	132
Impact of personalized medicine on other industries.....	132
Strategies for developing and marketing personalized medicine.....	133
<i>Education of the public</i>	133
<i>Role of the Internet in development of personalized medicine</i>	134
<i>Marketing companion diagnostics for personalized medicine</i>	134
14. Companies Involved in Developing Personalized Medicine.....	137
Introduction	137
Profiles	137
Collaborations.....	518
15 . R E F E R E N C E S	537

Tables

Table 11-1: Bayesian versus frequentist approaches in clinical trials	14
Table 11-2: Players in the development of personalized medicine	17
Table 11-3: Members of the Personalized Medicine Coalition	18
Table 11-4: Biobanks relevant to personalized medicine	55
Table 11-5: Role of bioinformatics in the development of personalized medicine.....	57
Table 11-6: Advantages of personalized medicine for the biopharmaceutical industry	77
Table 11-7: Advantages of personalized medicine for the patients	77
Table 11-8: Advantage of personalized medicine for the physicians.....	77
Table 11-9: Advantage of personalized medicine for the healthcare providers	77
Table 11-10: Limitations of personalized medicine	77
Table 11-11: Recommendations of the Association for Molecular Pathology on incidental findings	79
Table 11-12: Methods of translational science that are relevant to personalized medicine.....	82

Table 11-13: Companies involved in predictive healthcare	83
Table 11-14: Delivery for precision medicine.....	85
Table 12-1: Drugs with pharmacogenomic information in their labels	113
Table 13-1: Drivers for the development of personalized medicine	126
Table 13-2: Growth of markets relevant to personalized medicine 2020-2030	129
Table 13-3: Markets for personalized medicine according to therapeutic area 2020-2030..	131
Table 13-4: Markets for personalized medicine in major regions 2020-2030.....	131
Table 13-5: Lack of efficacy in current therapy	132
Table 13-6: Impact of personalized medicine on other industries	132
Table 13-7: Strategies to develop personalized medicine	133
Table 13-8: Role of the Internet in development of personalized medicine	134
Table 14-1: Top five pharmaceutical companies involved in personalized medicine	137
Table 14-2: Selected collaborations of companies in personalized medicine.....	518

Figures

Figure 13-1: Cost of sequencing per genome	119
Figure 13-2: Evolution of personalized medicine as a market driver	127